Skip to main content

Meaningful Life

Dear readers,

We have a wealth of information on the internet on how to live a meaningful life and mantras to obtain desired results.

Meaning of living a purposeful life is different for each individual. Each one's stake is different in life. In other words, we can say the purpose and intention of living a meaningful life are dependent on one's inner built and measure of happiness. For some it is about building purposeful connections; for some, it is about having wealth in life whereas for some it could be entirely different.

For me, the definition of living a meaningful life does not come without putting myself first on top of my priority list. I have to be able to carve time for myself, be able to take care of my needs, priorities and extend this definition next to my close family members and friends.

With that said, a good, healthy lifestyle has lately become a big focus of my agenda on a daily basis. Paying attention to what I eat, how much I eat, what I do to keep myself healthy in terms of the nutritious value of the food as well as exercise is on top of my list.

Additionally, keeping stress levels under control is considered to be very important. This could be as important as eating nutritious food.  Keeping stress under control is something that does not come easy and needs practice especially when everyone has so much to get done on a daily basis. Stress might cause chronic inflammation that could lead to an unhealthy life if stays unaddressed long-term.

I am starting this blog to learn and educate myself as well as share my learnings with anyone interested in the topic. I will focus on many different ways to manage and control stress. To practice certain things as routine to be able to at least reduce stress. It might be eating a certain type of foods, supplements or practice of mindfulness!

Comments

Post a Comment

Popular posts from this blog

Harmonization by Doing (HBD): Japan & U.S. Collaboration

BayBiotech.NET HBD is an international cooperative effort by Japan and US for regulatory convergence for Medical Devices. The efforts are focused on to develop global clinical trials and address regulatory barriers for timely device approvals. To address the needs for additional evaluation, the HBD initiative is a pilot project launched jointly by FDA and MHLW-PMDA for the premarket review of device cardiovascular technology. Instead of taking a theoretical approach to harmonization, HBD is focused on Proof of concept by utilizing parallel development, application submissions and review of actual medical device projects. HBD Study intends to collect and analyze regulatory submission data from multiple applications in the U.S. and Japan. The purpose of the study is to further understand differences that may exist with format and content, to define best practices and to improve globally harmonized processes. To read more about the HBD program, follow the link: http://www.fda.gov/M...
Post a Comment
Read more

Amendments for High Risk Device Type Regulatory Pathway

BayBiotech.NET Government Accounting Office (“GAO”) has issued a long-awaited report evaluating the use of the 510(k) process by the Food and Drug Administration (“FDA” or the “Agency”) in the January of 2009. Report mainly focused on Preamendment class III devices. Although most high-risk class III medical devices are subject to the demanding premarket approval (“PMA”) process, preamendment class III devices may be cleared through the 510(k) pathway until FDA issues regulations requiring a PMA. Under the Safe Medical Devices Act of 1990, FDA was required either to reclassify preamendment class III devices into class I or II, or (2) issue regulations requiring PMA approval for the devices, GAO noted that 20 preamendment class III device types have not yet been addressed by the Agency. GAO has urged FDA to take required steps to address the remaining class III devices that continue to be eligible for 510(k) review. As a result of the report, FDA has committed to address al...
Post a Comment
Read more

Risk Based Clinical Monitoring

BayBiotech.NET FDA's recommendation of Risk Based Monitoring of Clinical Trials , as published in their Draft Guidance in August 2011. For the first time, FDA provided guidance on monitoring of clinical investigations in 1988 which was recently withdrawn, stated that the “most effective way” to monitor an investigation was to “maintain personal contact between the monitor and the investigator throughout the clinical investigation.” At the time the guidance was issued, sponsors had only limited ways to effect meaningful communication with investigators other than through on-site visits.   This guidance recommends an assessment by the sponsor for the need of 100% on-site monitoring. Such an assessment may be based on the complexity of the study protocol and not be generally applicable to all trial types. It explains the importance of remote monitoring facilitated by the use of electronic data capture system (EDC) and also emphasizes the need of the identifying crit...
1 comment
Read more